HRP20120902T1 - Postupak lijeäśenja bolesti intraokularne neovaskularizacije - Google Patents
Postupak lijeäśenja bolesti intraokularne neovaskularizacije Download PDFInfo
- Publication number
- HRP20120902T1 HRP20120902T1 HRP20120902TT HRP20120902T HRP20120902T1 HR P20120902 T1 HRP20120902 T1 HR P20120902T1 HR P20120902T T HRP20120902T T HR P20120902TT HR P20120902 T HRP20120902 T HR P20120902T HR P20120902 T1 HRP20120902 T1 HR P20120902T1
- Authority
- HR
- Croatia
- Prior art keywords
- vegf
- individual doses
- antagonist
- administration
- vegf antagonist
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 4
- 201000010099 disease Diseases 0.000 title claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 24
- 239000005557 antagonist Substances 0.000 claims 24
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 108010081667 aflibercept Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Claims (15)
1. VEGF antagonist, naznačen time, da služi u postupku liječenja bolesti intraokularne neovaskularizacije kod ljudi pomoću intravitrealne primjene, pri čemu postupak obuhvaća:
a) primjenu tri početne individualne doze VEGF antagonista u jednomjesečnim intervalima; zatim slijedi
b) primjena šest drugih po redu individualnih doza antagonista, pri čemu
i) druge po redu individualne doze se primjenjuju manje frekventno nego početne individualne doze,
ii) tri početne individualne doze i šest drugih po redu individualnih doza se primjenjuju unutar perioda od dvije godine ili manje, i
iii) VEGF antagonist je anti-VEGF protutijelo, VEGF receptor ili njegov derivat koji veže VEGF, ili VEGF-blokator (VEGF-Trap).
2. VEGF antagonist prema zahtjevu 1, naznačen time, da bolest intraokularne neovaskularizacije je vlažni oblik makularne degeneracije povezane sa starošću.
3. VEGF antagonist prema zahtjevu 1 ili zahtjevu 2, naznačen time, da VEGF antagonist je anti-VEGF protutijelo.
4. VEGF antagonist prema zahtjevu 3, naznačen time, da anti-VEGF protutijelo je anti-VEGF protutijelo pune duljine.
5. VEGF antagonist prema zahtjevu 3, naznačen time, da anti-VEGF protutijelo je fragment protutijela.
6. VEGF antagonist prema zahtjevu 3, naznačen time, da anti-VEGF protutijelo je Fab fragment protutijela.
7. VEGF antagonist prema zahtjevu 5, naznačen time, da fragment protutijela je Y0317.
8. VEGF antagonist prema zahtjevu 1 ili zahtjevu 2, naznačen time, da VEGF antagonist je VEGF receptor ili njegov derivat koji veže VEGF.
9. VEGF antagonist prema zahtjevu 1 ili zahtjevu 2, naznačen time, da VEGF antagonist je VEGF-blokator (VEGF-Trap).
10. VEGF antagonist prema bilo kojem od prethodnih zahtjeva, naznačen time, da se druge po redu individualne doze primjenjuju u intervalima od tri mjeseca.
11. VEGF antagonist prema bilo kojem od prethodnih zahtjeva, naznačen time, da se druge po redu individualne doze primjenjuju tri mjeseca nakon prvog davanja početnih individualnih doza.
12. VEGF antagonist prema bilo kojem od prethodnih zahtjeva, naznačen time, da se tri početne individualne doze i šest drugih po redu individualnih doza primjenjuju unutar perioda od oko dvije godine.
13. VEGF antagonist prema bilo kojem od prethodnih zahtjeva, naznačen time, da postupak obuhvaća primjenu dodatnih doza nakon davanja šest drugih po redu individualnih doza.
14. Uporaba VEGF antagonista, naznačena time, da je za proizvodnju lijeka koji se koristi u postupku liječenja bolesti intraokularne neovaskularizacije kod ljudi pomoću intravitrealne primjene, pri čemu postupak obuhvaća:
a) primjenu tri početne individualne doze VEGF antagonista u jednomjesečnim intervalima; zatim slijedi
b) primjena šest drugih po redu individualnih doza antagonista, pri čemu
i) druge po redu individualne doze se primjenjuju manje frekventno nego početne individualne doze,
ii) tri početne individualne doze i šest drugih po redu individualnih doza se primjenjuju unutar perioda od dvije godine ili manje, i
iii) VEGF antagonist je anti-VEGF protutijelo, VEGF receptor ili njegov derivat koji veže VEGF, ili VEGF-blokator (VEGF-Trap).
15. Uporaba prema zahtjevu 14, naznačena time, da su bolest, sisavac, primjena i antagonist određeni u bilo kojem od zahtjeva 2 do 13.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62120904P | 2004-10-21 | 2004-10-21 | |
| PCT/US2005/038006 WO2006047325A1 (en) | 2004-10-21 | 2005-10-21 | Method for treating intraocular neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120902T1 true HRP20120902T1 (hr) | 2012-12-31 |
Family
ID=35708845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120902TT HRP20120902T1 (hr) | 2004-10-21 | 2012-11-08 | Postupak lijeäśenja bolesti intraokularne neovaskularizacije |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20070190058A1 (hr) |
| EP (4) | EP2319492A3 (hr) |
| AU (1) | AU2005299701B2 (hr) |
| CA (1) | CA2584305A1 (hr) |
| DK (1) | DK1802334T3 (hr) |
| ES (1) | ES2390676T3 (hr) |
| HK (1) | HK1102106A1 (hr) |
| HR (1) | HRP20120902T1 (hr) |
| NZ (3) | NZ590132A (hr) |
| PL (1) | PL1802334T3 (hr) |
| PT (1) | PT1802334E (hr) |
| RS (1) | RS52539B (hr) |
| SI (1) | SI1802334T1 (hr) |
| WO (1) | WO2006047325A1 (hr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101327270B1 (ko) | 2005-03-25 | 2013-11-08 | 리제네론 파라마큐티칼스 인코포레이티드 | 혈관내피성장인자 길항제 조제물 |
| WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US20070071754A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Method to ameliorate inflammation |
| DK1968594T3 (da) * | 2005-11-29 | 2010-12-13 | Glaxosmithkline Llc | Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| KR102095257B1 (ko) | 2008-06-25 | 2020-04-01 | 노바르티스 아게 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| CA2749026C (en) | 2008-09-29 | 2018-01-09 | Impala, Inc. | Heart valve |
| CA2739275C (en) | 2008-10-01 | 2017-01-17 | Impala, Inc. | Delivery system for vascular implant |
| CA2961053C (en) | 2009-04-15 | 2019-04-30 | Edwards Lifesciences Cardiaq Llc | Vascular implant and delivery system |
| AR078060A1 (es) * | 2009-07-14 | 2011-10-12 | Novartis Ag | Descontaminacion de superficie de contenedores previamente llenados en empaque secundario |
| WO2011017313A1 (en) * | 2009-08-04 | 2011-02-10 | Copernicus Therapeutics Inc. | Method of administering non-viral nucleic acid vectors to the eye |
| US20110104151A1 (en) * | 2009-10-01 | 2011-05-05 | Heather Nettles | Microparticle compositions and methods for treating age-related macular degeneration |
| US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
| MX349901B (es) | 2011-01-13 | 2017-08-18 | Regeneron Pharma | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
| US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
| EP2747811A4 (en) | 2011-08-23 | 2015-03-25 | Itech Jv Dev Company Llc | SYSTEMS AND METHODS FOR INJECTING |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
| BR112014029795B1 (pt) | 2012-06-01 | 2021-09-21 | Novartis Ag | Seringa oftálmica, pré-preenchida, terminalmente esterilizada e embalagem de seringa |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| AU2013100071C4 (en) * | 2012-07-03 | 2013-05-02 | Novartis Ag | Device |
| US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
| US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
| US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
| US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2015289124B2 (en) | 2014-07-18 | 2021-03-11 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| DK3384049T3 (da) | 2015-12-03 | 2023-10-02 | Regeneron Pharma | Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| RU2630202C1 (ru) * | 2016-09-30 | 2017-09-05 | Публичное акционерное общество "Газпром" | Способ извлечения фракции С2+ из сырого газа и установка для его осуществления |
| EP4306137A3 (en) | 2017-03-27 | 2024-04-03 | Regeneron Pharmaceuticals, Inc. | Sterilisation method |
| SG11202004268PA (en) | 2017-11-30 | 2020-06-29 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| CN117065152A (zh) | 2017-12-13 | 2023-11-17 | 里珍纳龙药品有限公司 | 用于精确剂量输送的装置和方法 |
| KR20200131839A (ko) | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| AU2020347575A1 (en) | 2019-09-13 | 2022-03-17 | Novartis Ag | Methods for treating ocular diseases |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TW202237181A (zh) | 2020-11-25 | 2022-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| WO2022201084A1 (en) | 2021-03-26 | 2022-09-29 | Novartis Ag | Methods for treating ocular diseases |
| TW202337496A (zh) | 2022-03-17 | 2023-10-01 | 瑞士商諾華公司 | 治療新生血管性年齡相關性黃斑點退化之方法 |
| WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| IT8121814V0 (it) | 1981-05-19 | 1981-05-19 | Nordica Spa | Struttura di scarpetta interna particolarmente per scarponi da sci. |
| US4456550A (en) * | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5008196A (en) * | 1987-08-21 | 1991-04-16 | Monsanto Company | Stimulation of endothelial cell growth |
| US5036003A (en) * | 1987-08-21 | 1991-07-30 | Monsanto Company | Antibodies to VPF |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223407A (en) | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5098833A (en) | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP1975181B1 (en) | 1992-10-28 | 2011-02-16 | Genentech, Inc. | Use of vascular endothelial cell growth factor antagonists |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| IL117645A (en) * | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| BR0010017A (pt) * | 1999-04-28 | 2002-06-11 | Univ Texas | Composições e processos para o tratamento de câncer por inibição seletiva de vegf |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| JP2005511576A (ja) * | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| US20050043220A1 (en) * | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| WO2005020972A2 (en) * | 2003-08-27 | 2005-03-10 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
| JP2010509369A (ja) * | 2006-11-10 | 2010-03-25 | ジェネンテック インコーポレイテッド | 加齢黄斑変性症を処置するための方法 |
-
2005
- 2005-10-21 RS RS20120491A patent/RS52539B/en unknown
- 2005-10-21 EP EP10181764A patent/EP2319492A3/en not_active Withdrawn
- 2005-10-21 NZ NZ590132A patent/NZ590132A/en not_active IP Right Cessation
- 2005-10-21 DK DK05816281.9T patent/DK1802334T3/da active
- 2005-10-21 SI SI200531618T patent/SI1802334T1/sl unknown
- 2005-10-21 EP EP05816281A patent/EP1802334B1/en not_active Revoked
- 2005-10-21 EP EP10181773A patent/EP2311433A3/en not_active Withdrawn
- 2005-10-21 PT PT05816281T patent/PT1802334E/pt unknown
- 2005-10-21 EP EP20100181761 patent/EP2324848A3/en not_active Withdrawn
- 2005-10-21 AU AU2005299701A patent/AU2005299701B2/en not_active Ceased
- 2005-10-21 CA CA002584305A patent/CA2584305A1/en not_active Abandoned
- 2005-10-21 PL PL05816281T patent/PL1802334T3/pl unknown
- 2005-10-21 NZ NZ598502A patent/NZ598502A/xx not_active IP Right Cessation
- 2005-10-21 ES ES05816281T patent/ES2390676T3/es active Active
- 2005-10-21 WO PCT/US2005/038006 patent/WO2006047325A1/en active Application Filing
- 2005-10-21 NZ NZ596663A patent/NZ596663A/xx not_active IP Right Cessation
-
2007
- 2007-04-20 US US11/738,284 patent/US20070190058A1/en not_active Abandoned
- 2007-07-26 HK HK07108111.0A patent/HK1102106A1/xx not_active IP Right Cessation
-
2012
- 2012-11-08 HR HRP20120902TT patent/HRP20120902T1/hr unknown
-
2013
- 2013-02-28 US US13/780,239 patent/US20140086934A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1802334A1 (en) | 2007-07-04 |
| EP2324848A3 (en) | 2011-09-14 |
| EP2311433A2 (en) | 2011-04-20 |
| DK1802334T3 (da) | 2012-10-15 |
| SI1802334T1 (sl) | 2012-12-31 |
| CA2584305A1 (en) | 2006-05-04 |
| EP2324848A2 (en) | 2011-05-25 |
| PT1802334E (pt) | 2012-11-28 |
| EP2319492A3 (en) | 2011-08-10 |
| US20070190058A1 (en) | 2007-08-16 |
| NZ590132A (en) | 2012-03-30 |
| ES2390676T3 (es) | 2012-11-15 |
| EP1802334B1 (en) | 2012-08-29 |
| EP2319492A2 (en) | 2011-05-11 |
| NZ598502A (en) | 2013-07-26 |
| PL1802334T3 (pl) | 2013-01-31 |
| US20140086934A1 (en) | 2014-03-27 |
| AU2005299701A1 (en) | 2006-05-04 |
| RS52539B (en) | 2013-04-30 |
| EP2311433A3 (en) | 2011-08-10 |
| NZ596663A (en) | 2013-07-26 |
| AU2005299701A2 (en) | 2006-05-04 |
| HK1102106A1 (en) | 2007-11-09 |
| WO2006047325A1 (en) | 2006-05-04 |
| AU2005299701B2 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120902T1 (hr) | Postupak lijeäśenja bolesti intraokularne neovaskularizacije | |
| Shaw et al. | Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus | |
| HRP20120893T1 (hr) | Formulacija protutijela na histidin-acetatnom puferu | |
| AU2004229527B2 (en) | Methods of preventing or treating respiratory conditions | |
| HRP20200185T1 (hr) | Metode za unaprjeđenje alergen-specifične imunoterapije primjenom inhibitora il-4r | |
| RS52793B (en) | PHARMACEUTICAL DOSAGE FORMS | |
| HRP20180445T1 (hr) | Il-22 za uporabu u liječenju mikrobnih poremećaja | |
| Scherer et al. | Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat | |
| HRP20191199T1 (hr) | Formulacije protutijela anti-prolaktinskog receptora | |
| HRP20221260T1 (hr) | Humanizirana i kimerna monoklonska protutijela za cd47 | |
| HRP20170419T1 (hr) | Sastavi za liječenje središnje posredovane mučnine i povraćanja | |
| JP2019531273A5 (hr) | ||
| HRP20170342T1 (hr) | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice | |
| CA2980992C (en) | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient | |
| HRP20211932T1 (hr) | Humana antitijela na fel d1 i postupci njihove upotrebe | |
| JP2010509369A5 (hr) | ||
| HRP20120934T1 (hr) | Sastavi i postupci koji koriste anti-cs1 antitijela u lijeäśenju multiplog mijeloma | |
| RS54156B1 (en) | COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS | |
| JP2014114288A5 (hr) | ||
| CY1115456T1 (el) | Μεθοδος χορηγησης αντισωματων αντι-ιl-5 | |
| JP2019504882A5 (hr) | ||
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| JP2018505882A5 (hr) | ||
| AR059213A1 (es) | Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal |